Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their insights on the occurrence and management of the most common hematologic and nonhematologic adverse events associated with several PARP inhibitors that are used as maintenance therapy in ovarian cancer.
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Videos — October 11, 2020
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
UCLA Health
Los Angeles, CA
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
The University of Arizona Cancer Center
Tucson, AZ
